Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02407457 · ClinicalTrials.gov registry record · NA
Post-Market Study to Assess Outcomes of Patients Treated With AFX System Compared to Other EVAR Devices
A NA study, sponsored by Endologix.
- Completed
- Registry status
- NA
- Development phase
- 455
- Enrollment target
NCT02407457: Completed NA study, sponsored by Endologix.
NCT02407457 is a NA study that has completed, run by Endologix. The registered enrollment target is 455 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02407457, a NA study, has completed, sponsored by Endologix.
- COMPLETED
- Registry status
- NA
- Development phase
- 455 participants
- Enrollment target
Study Summary
The objective of this post-market trial is to evaluate Endologix AFX endovascular AAA system with anatomical fixation against other approved Endovascular systems with proximal fixation. Multiple U.S clinical centers will be involved in the trial to include a broad range of experience. Imaging data will be evaluated by an independent core lab.
Primary Outcome
ARC is a composite of the most relevant EVAR outcomes and includes: * Peri-Operative Death (\< 30 days) * Rupture * Conversion to OSR * Endoleaks; post-operative * Migration (≥ 10mm) * Aneurysm Enlargement (≥ 5mm) * Endograft Limb Occlusions * Reinterventions for device- or aneurysm-related complications
Interventions
- DEVICE FDA Approved EVAR AAA Graft Systems
- DEVICE AFX EVAR AAA Graft System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 455 participants |
| Start Date | 2015-03 |
| Est. Completion | 2022-10 |
| Phase | NA |
What the finished NCT02407457 record still lists
NCT02407457 is an interventional study that assigns participants to a tested intervention. The registered 455 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 2 interventions - of which FDA Approved EVAR AAA Graft Systems is the first listed.
NCT02407457 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02407457 about?
NCT02407457 is a clinical study titled "Post-Market Study to Assess Outcomes of Patients Treated With AFX System Compared to Other EVAR Devices". The objective of this post-market trial is to evaluate Endologix AFX endovascular AAA system with anatomical fixation against other approved Endovascular systems with proximal fixation. Multiple U.S clinical centers will be involved in the trial to include a broad range of experience. Imaging data w...
What is the current status of trial NCT02407457?
This trial is currently completed. It is a NA study. The enrollment target is 455 participants. The study started on 2015-03. Estimated completion is 2022-10.
What interventions are being tested in trial NCT02407457?
The interventions under investigation include: FDA Approved EVAR AAA Graft Systems (DEVICE), AFX EVAR AAA Graft System (DEVICE).
Who is sponsoring clinical trial NCT02407457?
This trial is sponsored by Endologix, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02407457's enrollment target sits among peer trials
455 224th of 2000 higher than 1,777 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05541016 · 455 participants · Phase 2
De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
- NCT06079346 · 455 participants · Phase 2
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
- NCT06504446 · 455 participants · Phase 2
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough
- NCT06725030 · 455 participants
A Post-market, Real-world Experience: Expanding Access to Care by Incorporating the Symani® Surgical System and Enabling Surgeons
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia